In the fiercely competitive domestic heavy truck industry arena, Shaanxi Automotive Group Co., Ltd. continues to have a staggering move: In March 2009, the signing ceremony of the world's largest green passenger car cooperation project was held in Shaanxi Auto. Shenzhen Wuzhoulong Automobile Co., Ltd. provided 1,600 sets of environmentally friendly passenger car chassis, of which 1,000 were hybrid chassis and 600 were LNG passenger car chassis, marking a major breakthrough in the development and practical application of new energy technologies. . In April 2009, Shaanxi Automobile announced in Shanghai that it had established the first "Heavy Card New Energy Laboratory" in China and issued the first declaration of the heavy truck industry in China - "2009 Shan Auto Heavy Truck Green Declaration". As a result, Shaanxi Auto has opened the curtain to build its own brand of green, new energy and independent brands.

Since 2005, Shaanxi Automobile Group has jointed with Xi'an Jiaotong University, Chang'an University and other key institutions in accordance with market demand, and has taken the lead in the development of heavy-duty commercial vehicles with single-fuel natural gas engines in China, and has accumulated a lot of valuable experience for the new The development of energy commercial vehicles has laid a solid foundation. During the “Eleventh Five-Year Plan” period, Shaanxi Automobile Group successively undertook two major project topics of the “National 863” new energy commercial vehicle, and successfully developed large-capacity heavy-duty trucks and bus chassis for liquefied natural gas (LNG) and compressed natural gas (CNG). As well as new energy products such as micro-electric axles, it has gradually formed its industrialization pattern. Among them, CNG and LNG heavy trucks have a number of patented technologies that fill the gaps in China's natural gas heavy truck products. The sales volume of the products is the first in the country and it is exported to foreign markets. In addition, Shaanxi Automobile Group has made new breakthroughs in electric commercial vehicles and passenger car products. Electric vehicle low-speed tractors, hybrid urban trucks, and DME vehicles have entered the R&D pilot stage. Since 2007, the company has sold nearly 1,000 CNG, LNG heavy trucks and nearly 1,000 CNG and LNG passenger car chassis. The heavy trucks and passenger cars of CNG and LNG products have taken the leading position in the industry and have the largest market share in the country.

According to reports, Shaanxi LNG and CNG heavy-duty vehicles produced by Shaanxi Auto use clean, cheap natural gas as fuel, which greatly reduces energy consumption. Natural gas prices are more than 40% lower than the price of fuel, which saves users costs. Shaanxi Automobile's natural gas heavy-duty truck exhaust does not contain sulfides and lead, reducing carbon monoxide emissions by 80%, hydrocarbons by 60%, and nitrogen oxides by 70%, greatly reducing pollutant emissions. At the same time, Shaanxi Steam is also the first domestic CNG heavy truck developed and put into the market in batches. The CNG and LNG natural gas pioneer products introduced have been hailed as China's low-carbon and heavy-duty technology era energy-saving leaders, and the maximum cruising range is 1,000 kilometers. It is estimated that by 2012, the new energy bus products will account for 50% of the total buses of the Shaanxi Automobile Group, and will reach an annual output of 5,000 miniature electric vehicles and 60,000 miniature electric vehicle axles, which will be the industry leader.

[Composition]

The main component of this preparation is human immunoglobulin, which is prepared by cold ethanol fractionation of human plasma from healthy donors. The manufacturing process contains a step to remove anticomplementary activity and a dual viral inactivation process. It contains a suitable amount of glucose or maltose as stabilizer (see table below), but does not contain any antiseptic or antibiotic. The distribution of IgG subclasses is close to the serum level of normal subjects and maintains the bioactivity of Fc fragment of IgG.

[Indications]

1. Primary agammaglobulinemia, such as X-linked hypogammaglobulinemia, common variant immunodeficiency diseases, immunoglobulin G subclass deficiency, etc.

2. Secondary immunoglobulin deficiency diseases, such as severe infection, septicemia of newborn, etc

3. Autoimmune diseases, such as primary thrombocytopenic purpura, Kawasaki disease

Intravenous Injection Of Human Immunoglobulin

Intravenous Injection Of Human Immunoglobulin,Intravenous Immunoglobulin,High-Quality Effective Intravenous Immunoglobulin,Human Immunoglobulin For Intravenous Injection

Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. , https://www.syimmunoglobulin.com